시장보고서
상품코드
1728035

세계의 심내막 심근 생검 시장 : 시장 규모 및 점유율 및 동향 분석(제품별, 칩별, 최종 용도별, 지역별), 부문별 예측(2025-2030년)

Endomyocardial Biopsy Market Size, Share & Trends Analysis Report By Product (Forceps, Accessories), By Tip (Straight, Pre-curved), By End-use (Hospitals, Ambulatory Surgical Centers), By Region, And Segment Forecasts, 2025 - 2030

발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 130 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

심내막 심근 생검 시장의 성장 및 동향 :

Grand View Research, Inc의 최신 보고서에 따르면 세계의 심내막 심근 생검 시장은 2030년까지 5억 4,300만 달러에 이를 것으로 예측되며, 2025년부터 2030년까지 연평균 성장률(CAGR) 6.9%로 성장할 것으로 예측됩니다.

이 시장의 성장은 심혈관 질환(CVD)의 유병률 증가, 최소 침습 수술에 대한 수요 증가, 관상동맥 중재 시술에 대한 유리한 환급 정책 등의 요인에 기인합니다.

기술 발전과 다국적 기업의 신흥국 투자 증가는 시장의 성장과 확장을 위한 이상적인 기회로 작용합니다. 신흥 경제국에서는 의료 개혁과 의료 제품 및 기기에 대한 기술 발전이 이루어지고 있습니다. 이는 제조업체가 제품을 소개하고 시장의 상당 부분을 점유할 수 있는 기회를 제공합니다. 인도, 중국 등의 국가는 의료 시스템을 발전시키고 점진적인 변화를 가져와 환자에게 향상된 치료 옵션을 제공하고 있습니다.

또한 선진국에서는 의료 인프라가 잘 구축되어 있어 첨단 진단 및 치료 옵션에 쉽게 접근할 수 있습니다. 미국 장기 공유 연합 네트워크에서 발표한 데이터에 따르면2022년에는 미국에서 4,111건 이상의 심장 이식이 이루어졌습니다.

심내막 심근 생검 시장 : 분석 개요

  • 겸자 부문은 주로 심혈관 질환의 유병률 증가와 의료 기술의 발전에 힘입어 2024년 71.9%의 가장 큰 매출 점유율로 제품 부문을 지배했습니다.
  • 액세서리는 심장 시술 건수 증가와 특수 도구의 필요성으로 인해 예측 기간 동안 6.3%의 수익성 높은 연평균 성장률로 성장할 것으로 예상됩니다.
  • 직선형 팁 부문이 세계의 심내막 심근 생검 시장을 독점하고, 2024년에는 36.2%의 최대 매출 점유율을 차지했습니다.
  • 곡선 칩은 복잡한 심장 해부학 구조를 탐색하기위한 향상된 조작성과 능력으로 예측 기간 동안 높은 CAGR로 성장할 것으로 예측됩니다.
  • 2024년, 병원이 최대의 수익 점유율을 차지했습니다. 외래수술센터(ASC) 부문은 예측 기간에 CAGR 6.0%로 성장할 것으로 예측됩니다.
  • 북미는 2024년에 세계의 심내막 심근 생검 시장에서 가장 큰 매출 점유율을 차지했습니다.
  • 아시아태평양 시장은 2025년부터 2030년까지 가장 빠른 CAGR로 성장할 것으로 예측되고 있습니다.

목차

제1장 분석 방법 및 범위

제2장 주요 요약

제3장 심내막 심근 생검 시장 : 변동 요인 및 경향 및 범위

  • 시장 연관 전망
    • 상위 시장 전망
    • 관련 및 하위 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 심내막 심근 생검 시장 : 분석 도구
    • 업계 분석 : Porter's Five Forces 분석
    • PESTEL 분석

제4장 세계의 심내막 심근 생검 시장 : 제품별 비즈니스 분석

  • 제품별 대시보드
  • 심내막 심근 생검 시장 : 동향 분석, 제품별
  • 세계의 심내막 심근 생검 시장 규모 및 동향 분석 : 제품별(2018-2030년)
  • 겸자
  • 액세서리

제5장 세계의 심내막 심근 생검 시장 : 칩별 비즈니스 분석

  • 칩별 대시보드
  • 심내막 심근 생검 시장 : 동향 분석, 칩별
  • 세계의 심내막 심근 생검 시장 규모 및 동향 분석 :칩별(2018-2030년)
  • 가동식
  • 직선형
  • 곡선형
  • 기타

제6장 세계의 심내막 심근 생검 시장 : 최종 용도별 비즈니스 분석

  • 최종 용도별 대시보드
  • 심내막 심근 생검 시장 : 동향 분석, 최종 용도별
  • 세계의 심내막 심근 생검 시장 규모 및 동향 분석 : 최종 용도별(2018-2030년)
  • 병원
  • 외래수술센터(ASC)
  • 기타

제7장 세계의 심내막 심근 생검 시장 : 지역별 추정 및 동향 분석

  • 시장 대시보드: 지역별
  • 시장 점유율 분석 : 지역별(2024년, 2030년)
  • 세계의 심내막 심근 생검 시장 : 주요 포인트, 지역별
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 스페인
    • 덴마크
    • 스웨덴
    • 노르웨이
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 태국
    • 한국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 쿠웨이트

제8장 경쟁 구도

  • 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
  • 기업 및 경쟁 분류
  • 벤더 상황
    • 주요 기업의 히트맵 분석(2024년)
  • 기업 프로파일
    • Argon Medica Devices, Inc.
    • Cordis
    • Mermaid Medical
    • Terumo Corporation
    • Scholten Surgical Instruments, Inc.
    • Changzhou Lookmed Medical Instrument Co., Ltd.
    • Fehling Instruments
HBR 25.05.30

Endomyocardial Biopsy Market Growth & Trends:

The global endomyocardial biopsy market is anticipated to reach USD 543.0 million by 2030 and is anticipated to expand at a CAGR of 6.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to factors such as increasing prevalence of Cardiovascular Disorders (CVDs), rising demand for minimally invasive surgical procedures, and favorable reimbursement policies for coronary intervention procedures.

An increase in technological advancements and investment of multinational companies in emerging economies serve as ideal opportunities for the growth and expansion of a market. There is a trend of healthcare reforms and advancements in technology for medical products and devices in emerging economies. This creates an opportunity for manufacturers to introduce their products and capture a significant portion of the market. Countries like India, China, and others are developing and are bringing about incremental changes to their healthcare systems, providing enhanced treatment options to patients.

Furthermore, the well-established healthcare infrastructure in developed countries enables easy accessibility to advanced diagnostic and treatment options. According to data published by the United Network for Organ Sharing, in 2022, over 4,111 heart transplants were performed in the U.S. As the number of heart transplants increases, the need for regular monitoring and early detection of rejection would also increase. This would further boost the demand for endomyocardial biopsy procedures.

Endomyocardial Biopsy Market Report Highlights:

  • The forceps segment dominated the product segment with the largest revenue share of 71.9% in 2024, primarily driven by the growing prevalence of cardiovascular diseases and advancements in medical technology.
  • Accessories are expected to grow at a lucrative CAGR of 6.3% growth over the forecast period, owing to the rising number of cardiac procedures and the need for specialized tools.
  • The straight tip segment dominated the global endomyocardial biopsy market and held the largest revenue share of 36.2% in 2024, attributed to their precision, ease of use, and suitability for routine procedures as well as their straightforward design, which allows for efficient tissue collection, reducing procedure time and enhancing sample reliability.
  • Pre-curved tips are expected to grow at a significant CAGR over the forecast period, driven by their enhanced maneuverability and capability to navigate complex cardiac anatomy.
  • Hospital held the largest revenue share in 2024. The ambulatory surgery center (ASC) segment is anticipated to grow at a CAGR of 6.0% over the forecast period.
  • North America dominated the global endomyocardial biopsy market with the largest revenue share in 2024, driven by advanced healthcare infrastructure, increasing prevalence of cardiovascular diseases, rising heart transplant procedures, and growing awareness of early disease diagnosis.
  • Asia Pacific market is projected to grow at the fastest CAGR from 2025 to 2030, attributed to a rising geriatric population, increasing occurrence of cardiac disorders, improving healthcare access, and government initiatives.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Tip
    • 1.2.3. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product Outlook
    • 2.2.2. Tip Outlook
    • 2.2.3. End Use Outlook
    • 2.2.4. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Global Endomyocardial Biopsy Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Global Endomyocardial Biopsy Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
      • 3.3.2.1. Political Landscape
      • 3.3.2.2. Technological Landscape
      • 3.3.2.3. Economic Landscape

Chapter 4. Global Endomyocardial Biopsy Market: Product Business Analysis

  • 4.1. Product Segment Dashboard
  • 4.2. Endomyocardial Biopsy Market: Product Movement Analysis
  • 4.3. Global Endomyocardial Biopsy Market Size & Trend Analysis, By Product, 2018 to 2030 (USD Million)
  • 4.4. Forceps
    • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5. Accessories
    • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Global Endomyocardial Biopsy Market: Tip Business Analysis

  • 5.1. Tip Segment Dashboard
  • 5.2. Endomyocardial Biopsy Market: Tip Movement Analysis
  • 5.3. Global Endomyocardial Biopsy Market Size & Trend Analysis, By Tip, 2018 to 2030 (USD Million)
  • 5.4. Maxi-curved
    • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5. Straight
    • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6. Pre-curved
    • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Global Endomyocardial Biopsy Market: End Use Business Analysis

  • 6.1. End Use Segment Dashboard
  • 6.2. Endomyocardial Biopsy Market: End Use Movement Analysis
  • 6.3. Global Endomyocardial Biopsy Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5. Ambulatory Surgical Centers
    • 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Global Endomyocardial Biopsy Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2024 & 2030
  • 7.3. Global Endomyocardial Biopsy Market by Regional: Key Takeaways
  • 7.4. North America
    • 7.4.1. U.S.
      • 7.4.1.1. Key Country Dynamics
      • 7.4.1.2. Regulatory Framework/ Reimbursement Structure
      • 7.4.1.3. Competitive Scenario
      • 7.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Canada
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework/ Reimbursement Structure
      • 7.4.2.3. Competitive Scenario
      • 7.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Mexico
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework/ Reimbursement Structure
      • 7.4.3.3. Competitive Scenario
      • 7.4.3.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Germany
      • 7.5.1.1. Key Country Dynamics
      • 7.5.1.2. Regulatory Framework/ Reimbursement Structure
      • 7.5.1.3. Competitive Scenario
      • 7.5.1.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework/ Reimbursement Structure
      • 7.5.2.3. Competitive Scenario
      • 7.5.2.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.5.3. France
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework/ Reimbursement Structure
      • 7.5.3.3. Competitive Scenario
      • 7.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Italy
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework/ Reimbursement Structure
      • 7.5.4.3. Competitive Scenario
      • 7.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Spain
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework/ Reimbursement Structure
      • 7.5.5.3. Competitive Scenario
      • 7.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Denmark
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework/ Reimbursement Structure
      • 7.5.6.3. Competitive Scenario
      • 7.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Sweden
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework/ Reimbursement Structure
      • 7.5.7.3. Competitive Scenario
      • 7.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.5.8. Norway
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework/ Reimbursement Structure
      • 7.5.8.3. Competitive Scenario
      • 7.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key Country Dynamics
      • 7.6.1.2. Regulatory Framework/ Reimbursement Structure
      • 7.6.1.3. Competitive Scenario
      • 7.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework/ Reimbursement Structure
      • 7.6.2.3. Competitive Scenario
      • 7.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.6.3. India
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework/ Reimbursement Structure
      • 7.6.3.3. Competitive Scenario
      • 7.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Australia
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework/ Reimbursement Structure
      • 7.6.4.3. Competitive Scenario
      • 7.6.4.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Thailand
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework/ Reimbursement Structure
      • 7.6.5.3. Competitive Scenario
      • 7.6.5.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework/ Reimbursement Structure
      • 7.6.6.3. Competitive Scenario
      • 7.6.6.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key Country Dynamics
      • 7.7.1.2. Regulatory Framework/ Reimbursement Structure
      • 7.7.1.3. Competitive Scenario
      • 7.7.1.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Argentina
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework/ Reimbursement Structure
      • 7.7.2.3. Competitive Scenario
      • 7.7.2.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.8. Middle East & Africa
    • 7.8.1. South Africa
      • 7.8.1.1. Key Country Dynamics
      • 7.8.1.2. Regulatory Framework/ Reimbursement Structure
      • 7.8.1.3. Competitive Scenario
      • 7.8.1.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework/ Reimbursement Structure
      • 7.8.2.3. Competitive Scenario
      • 7.8.2.4. South Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework/ Reimbursement Structure
      • 7.8.3.3. Competitive Scenario
      • 7.8.3.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.8.4. Kuwait
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework/ Reimbursement Structure
      • 7.8.4.3. Competitive Scenario
      • 7.8.4.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key Company Heat Map Analysis, 2024
  • 8.4. Company Profiles
    • 8.4.1. Argon Medica Devices, Inc.
      • 8.4.1.1. Company Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Cordis
      • 8.4.2.1. Company Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. Mermaid Medical
      • 8.4.3.1. Company Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Terumo Corporation
      • 8.4.4.1. Company Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Scholten Surgical Instruments, Inc.
      • 8.4.5.1. Company Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Changzhou Lookmed Medical Instrument Co., Ltd.
      • 8.4.6.1. Company Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. Fehling Instruments
      • 8.4.7.1. Company Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제